Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates
Listen now
Description
Nadia Harhen, general manager of simulation and optimization for SandboxAQ, discusses the challenges of drug development it is seeking to address, how Sandbox AQ is leveraging quantum technologies, and why it is seeking to tackle an intractable set of diseases.
More Episodes
Bobby Azamian, CEO of Tarsus, discusses Lyme disease, the case for the company’s experimental prophylactic drug TP-05, and why you may already have been using a form of the drug to protect a four-legged member of your household.
Published 05/01/24
Jason Bock, CEO of CMTC, the joint venture between Resilience and MD Anderson Cancer Center, discusses the emerging area of TIL therapies, the significance of the first approved therapy in the class, and how they may address existing limitations of CAR-T therapies.
Published 04/24/24
Published 04/24/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
